Close

Immunomedics (IMMU) Receives FDA Oprhan Drug Designation for Veltuzumab as Pemphigus Treatment

November 21, 2014 8:31 AM EST Send to a Friend
Immunomedics (NASDAQ: IMMU) announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login